November 2019 in “Harper's Textbook of Pediatric Dermatology” This index of Harper's Textbook of Pediatric Dermatology, Fourth Edition, provides no clinical results or new findings.
April 2016 in “Plastic and reconstructive surgery. Global open” This article from the PRS Global Open and ASPS Education Network does not present any new research findings; it likely serves as an introductory or descriptive overview.
34 citations
,
June 2015 in “Journal of cardiovascular pharmacology and therapeutics” This article discusses the use of direct vasodilators and sympatholytic agents in hypertension management, highlighting their utility in specific cases like refractory hypertension and heart failure, but reports no new clinical results.
40 citations
,
July 2011 in “The journal of clinical hypertension” This article reviews the use of hydralazine, minoxidil, and sodium nitroprusside in managing hypertension and hypertensive crises, noting specific indications, adverse effects, and the adjunctive therapies needed to mitigate side effects.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
1 citations
,
October 1974 in “Postgraduate medicine” New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
January 1983 in “Side effects of drugs annual” This chapter reviews adverse effects of anti-anginal and beta-blocker drugs, stating that starting a beta-blocker may temporarily affect driving ability, but it reports no new clinical findings.
June 2023 in “Frontiers in Cardiovascular Medicine” This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.
March 2005 in “The Nurse Practitioner” This update provides information on new drug approvals but does not offer new clinical research findings.
17 citations
,
May 1975 in “Clinical Pharmacology & Therapeutics”
This study in diabetic db/db mice found that treatment with the antihypertensive agents minoxidil or nebivolol stimulated elastogenesis and inhibited elastolysis, leading to restored elastic fibers, reduced aortic stiffening, and normalized blood pressure.
34 citations
,
January 1977 in “American Journal of Cardiology”
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
14 citations
,
April 2009 in “Acta Medica Scandinavica” In this study, oral minoxidil combined with other medications improved blood pressure control in patients with severe hypertension but often had to be discontinued due to side effects.
25 citations
,
December 1974 in “Clinical Pharmacology & Therapeutics” Propranolol affects heart rate and renin levels in minoxidil-treated patients.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” This review discusses the therapeutic potential of potassium channel openers for various conditions, but notes that their clinical role is not yet fully established.
57 citations
,
February 1975 in “Journal of Clinical Investigation” This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.
73 citations
,
September 2016 in “Journal of Translational Medicine” This review discusses the drug repurposing of cardiovascular medications like aspirin and statins for new uses, including potential anti-tumor effects, noting promising experimental outcomes but less conclusive clinical trials, particularly in the field of cancer treatment.
September 2004 in “Inpharma Weekly” April 2011 in “The FASEB Journal” This research found that prolonged doses of Amlodipine at 5mg/kg BW or higher impaired fertility indicators in adult male rats, affecting sperm morphology, count, and motility.
This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.
1 citations
,
October 1990 in “The Lancet” Using minoxidil for hair growth may cause skin lesions in some people, and taking breaks from nitrate patches for angina might worsen symptoms.
48 citations
,
June 1988 in “PubMed” In this study, minoxidil sulfate was found to relax norepinephrine-induced contractions in rabbit mesenteric arteries, possibly by acting as a K+ channel agonist, but it did not relax K+-induced contractions.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
50 citations
,
September 1975 in “American Heart Journal” Minoxidil effectively controls blood pressure in severe cases, but may cause fluid retention and edema.
This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.
55 citations
,
October 1975 in “Circulation” Minoxidil, propranolol, and furosemide effectively control severe hypertension, but may cause sodium retention.